Overview

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Status:
Not yet recruiting

Trial end date:
2034-10-01

Target enrollment:

Participant gender:

Summary

This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the risk of chronic rejection and, ultimately, the need for repeated transplantation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Alice Bertaina

Treatments:

Cyclophosphamide
Fludarabine
Melphalan
Rituximab